Mochida Pharmaceutical Co., Ltd.

Naoto Kosuga

Daido Hotta

Tsutomu Satoh

Yoshitaka Maeda

Yasushige Akada

Tomoyuki Kamino

Hideharu Uchida

Ken-ichi Amano

Akihiro Okano

Munetaka Ohkouchi

Muneyoshi Makabe

Ken-Ichi Amano

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I):  (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, &#x2014;NR&#x2014;; and Rto Rare specific groups), a salt of the compound, or a solvate of the salt or the compound.

3-hydroxy-5-arylisothiazole derivative

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; Rrepresents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NOgroup, or the like; Rrepresents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; Xrepresents O, &#x2014;NR&#x2014;, or &#x2014;S(O)r-; Xrepresents a methylene group, O, &#x2014;NR&#x2014;, or &#x2014;S(O)r-; Q&#x2032; represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

Heterocyclidene acetamide derivative

Growing community of inventors

Tokyo, Japan

Naoto Kosuga